

Apple Jumps, Goldman Rises, Pfizer Lower After Abandoning Obesity Pill
Apr 14, 2025
In this discussion, Apple sees a significant share rally thanks to tariff exemptions for its products. Goldman Sachs shines with record quarterly revenue, driven by market volatility. Meanwhile, Pfizer takes a hit as it halts its obesity drug trial due to concerns over liver damage. These developments not only impact individual stocks but also reshape the broader market dynamics.
AI Snips
Chapters
Transcript
Episode notes
Apple's Temporary Relief
- Apple shares rallied after a temporary tariff exemption on electronics.
- This reprieve seems temporary, causing uncertainty for Apple.
Goldman Sachs' Trading Boom
- Goldman Sachs stock traders achieved record quarterly revenue.
- This success is attributed to the volatility in financial markets, driven by the ongoing trade war.
Goldman Sachs' M&A Concerns
- Goldman Sachs CEO David Solomon notes a slowdown in M&A activity.
- This is due to uncertainty surrounding the White House's stance on deals.